Trending Now
Leap Therapeutics Inc. (NASDAQ: LPTX) To Update DisTinGuish Study Results On...
Leap Therapeutics Inc. (NASDAQ: LPTX) has announced that they will update results from the DisTinGuish study, a phase 2a clinical study investigating its ant-Dickkopf...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Galera Therapeutics Inc (NASDAQ:GRTX) Reports Updated Results Of Phase 1/ 2...
Galera Therapeutics Inc (NASDAQ:GRTX) issued an update on multi-centre, double-blind, randomized and placebo-controlled Phase 1/2 clinical study results of GC4419 in SBRT treated patients...
MAKE IT MODERN
LATEST REVIEWS
BeyondSpring (NASDAQ: BYSI) Enter Co-development And Commercialization Agreement With Jiangsu Hengrui...
BeyondSpring (NASDAQ: BYSI) has announced an exclusive co-development and commercialization agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd in Greater China for BeyondSpring’s experimental drug...
MAKE IT MODERN
PERFORMANCE TRAINING
Is Eco Innovation Group, Inc. (OTCMKTS:ECOX) an ESG Monster in the Making?
The ESG investment opportunity is likely to define the marketplace for the next decade. So say Morgan Stanley, Goldman Sachs, and Bank of America...
Investing in the Coming Oil Boom (MTDR, AGYP, FANG)
OPEC-plus, the extended version of OPEC that came together several years ago to drive more policy power back into the global cartel-based...
SIGA Technologies Inc (NASDAQ: SIGA) Receives UK Approval for Oral TPOXX For Monkeypox, Cowpox,...
SIGA Technologies Inc (NASDAQ: SIGA) has announced that it has received approval from the UK for oral tecovirimat (popular as Oral TPOXX in the...
Omeros Corporation (NASDAQ:OMER) Publishes Final Safety And Efficacy Data From Narsoplimab Stem Cell Transplantation...
Omeros Corporation (NASDAQ:OMER) recently disclosed its comprehensive final findings of its clinical trial evaluating narsoplimab’s performance in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Narsoplimab...
InflaRX N.V. (NASDAQ: IFRX) Reports positive Phase II IXCHNAGE Study Findings on Vilobelimab in...
InflaRX N.V. (NASDAQ: IFRX) has announced positive findings from the Phase II IXCHANGE trial of its first in class anti-C5a antibody, vilobelimab, in treating...
MAKE IT MODERN
